Amedisys Inc

Amedisys — Q3 2023 Earnings Presentation

16 slides from Amedisys's earnings presentation, Oct 24, 2023

  1. Slide 1: Amedisys Third Quarter 2023 Earnings Release Supplemental Slides

    1 Amedisys Third Quarter 2023 Earnings Release Supplemental Slides October 24th, 2023 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    2 This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could c

  3. Slide 3: Our Key Areas of Focus

    3 OUR KEY AREAS OF FOCUS Strategic areas of focus and progress made during Q3’23 • Home Health: Total same store admissions +4% • Hospice: Total same store ADC -2% • High Acuity Care: Admissions +35% over prior year 1 Organic Growth • Quality: Amedisys Jan’24 preview STARS score of 4.41 • 96% of car

  4. Slide 4: Highlights and Summary Financial Results (Adjusted): 3Q23

    4 HIGHLIGHTS AND SUMMARY FINANCIAL RESULTS (ADJUSTED): 3Q 2023(1) Excluding the sale of our personal care segment, our revenue increased $14 million over prior year. EBITDA is down $4 million; however, prior year benefited from the reversal of incentive compensation accruals based on performance and

  5. Slide 5: Revenue Mix and Reimbursement by Payor

    5 62.0%11.7% 26.3% Home Health Revenue Medicare FFS Private Episodic Per Visit 63.2% 36.0% 0.8% Amedisys Consolidated Revenue Home Health Hospice High Acuity Care • Medicare FFS: Reimbursed for a 30-day period of care • Private Episodic: MA and Commercial plans who reimburse us for a 30-day period o

  6. Slide 6: Home Health and Hospice Segment (Adjusted) – Q3 2023

    6 HOME HEALTH AND HOSPICE SEGMENT (ADJUSTED) – Q3 2023(1) • Revenue per Episode up 0.8% due to patient mix (wage index and functional score are primary drivers). Reimbursement is flat year over year. • Y/Y Total CPV up $5.21 (+4.7%) primarily due to raises, wage inflation, an increase in new hire pa

  7. Slide 7: General & Administrative Expenses – Adjusted

    7 $ in Millions 3Q22 4Q22 1Q23 2Q23 3Q23 Home Health Segment - Total 87.7 89.9 89.0 90.1 91.3 % of HH Revenue 25.9% 26.2% 25.9% 25.8% 26.0% Hospice Segment - Total 48.6 50.8 47.9 47.9 48.4 % of HSP Revenue 24.4% 25.7% 24.8% 24.0% 24.2% Personal Care Segment - Total 2.3 2.4 2.2 - - % of PC Revenue 14

  8. Slide 8: Operational Excellence: Home Health Cost per Visit (CPV) – Adjusted

    8 OPERATIONAL EXCELLENCE: HOME HEALTH COST PER VISIT (CPV)-ADJUSTED YOY Total CPV impacted by labor cost. *Note: Direct comparison with industry competitors CPV calculation ** Note: In 3Q’22, the addback of COVID costs reduced Visiting Clinician CPV by $0.81. Accordingly, our YOY increase is $3.86 o

  9. Slide 9: Driving Top Line Growth

    9 DRIVING TOP LINE GROWTH 1% 1% 5% 3% 3% 5% 5% 8% 4% 4% -4.0% -2.0% 0.0% 2.0% 4.0% 6.0% 8.0% 50,000 100,000 150,000 3Q22 4Q22 1Q23 2Q23 3Q23 Volume SS Volume Growth SS Admit Growth Home Health Growth Hospice Growth 1% -2% -1% -2% -2% -2.5% -0.5% 1.5% 12,500 12,750 13,000 13,250 13,500 3Q22 4Q22 1Q23

  10. Slide 10: Industry Leading Quality Scores

    10 INDUSTRY LEADING QUALITY SCORES Quality of Patient Care (QPC) Patient Satisfaction (PS) • Amedisys maintains a 4-Star average in the Jan 2024 HHC Preview with 96% of our providers (representing 96% of care centers) at 4+ Stars and 73% of our providers (representing 73% of care centers) at 4.5+ St

  11. Slide 11: Hospice Quality: Moving Towards Best-in-Class

    11 HOSPICE QUALITY: AMEDISYS HOSPICE CONTINUES TO MOVE TOWARDS BEST-IN-CLASS Hospice Quality Notes: Included in the above analysis are only active providers.

  12. Slide 12: Debt and Liquidity Metrics

    12 DEBT AND LIQUIDITY METRICS Net leverage ~1.2x 1. Net debt defined as total debt outstanding ($405.0M) less cash ($94.0M). 2. Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA ($250.2M). 3. Liquidity defined as the sum of cash balance and available revolving

  13. Slide 13: Cash Flow Statement Highlights

    13 CASH FLOW STATEMENT HIGHLIGHTS (1) Total cash flow from operations for Q3-23 impacted by delays in billing resulting from payor rate changes. 1. Free cash flow defined as cash flow from operations less routine capital expenditures and required debt repayments. $ in Millions 3Q22 4Q22 1Q23 2Q23 3Q

  14. Slide 14: Income Statement Adjustments

    14 INCOME STATEMENT ADJUSTMENTS (1) 1. The financial results for the three-month periods ended September 30, 2022, December 31, 2022, March 31, 2023, June 30, 2023 and September 30, 2023 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these n

  15. Slide 15: Environmental, Social, Governance (E.S.G.) Considerations

    15 Environmental, Social, Governance (E.S.G.) Considerations

  16. Slide 16: Environmental, Social, Governance (E.S.G.) Considerations

    16 ENVIRONMENTAL, SOCIAL, GOVERNANCE (E.S.G.) CONSIDERATIONS Sustainable, high-quality, patient focused, home-based care model Environmental • Amedisys is dedicated to the sustainability of our business and the communities in which we serve • Environmental health has a strong correlation with physic

Amedisys — Q3 2023 Earnings Presentation on 6ix